DGIdb - LENVATINIB Drug Record

LENVATINIB chembl:CHEMBL1289601 ApprovedAntineoplastic

Alternate Names:

E-7080
ER-203492-00
LENVIMA
LENVATINIB
KISPLYX
E7080
LENVIMA®
E 7080
UNII-EE083865G2
4-(3-CHLORO-4-(N'-CYCLOPROPYLUREIDO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE
LENVATINIB MESYLATE
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
chemidplus:417716-92-8
chembl:CHEMBL1289601
rxcui:1603296
drugbank:09078
pubchem.compound:9823820

Drug Info:

FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
FDA Approval	Renal cell carcinoma, Thyroid cancer
Drug Class	Kinase Inhibitors

(4 More Sources)

Publications:

Matsui et al., 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition., Int. J. Cancer
Tohyama et al., 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models., J Thyroid Res
Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.
Hong et al., 2015, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma., Clin. Cancer Res.

LENVATINIB RET

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 27496134 17943726

Sources:
TALC JAX-CKB CIViC
LENVATINIB FLT4

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TALC MyCancerGenome TdgClinicalTrial
LENVATINIB FGFR1

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 17943726

Sources:
TdgClinicalTrial JAX-CKB
LENVATINIB NRAS

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26169970

Sources:
JAX-CKB
LENVATINIB KDR

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

Notes

PMIDs:
17943726

Sources:
TALC MyCancerGenome TdgClinicalTrial TTD
LENVATINIB FGFR2

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
17943726

Sources:
TALC
LENVATINIB FLT1

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

Notes

PMIDs:
17943726

Sources:
TALC TdgClinicalTrial
LENVATINIB KIT

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TdgClinicalTrial
LENVATINIB PDGFRA

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TdgClinicalTrial
LENVATINIB BRAF

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
26169970

Sources:
JAX-CKB
LENVATINIB PDGFRB

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
LENVATINIB YES1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: LENVATINIB
- Version: 20-Jun-2017
Alternate Names:

LENVATINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Renal cell carcinoma, Thyroid cancer

Publications:
TdgClinicalTrial: LENVATINIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Lenvatinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Hong et al., 2015, Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma., Clin. Cancer Res.

Tohyama et al., 2014, Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models., J Thyroid Res

CIViC: LENVATINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.
DTC: LENVATINIB
- Version: 02-September-2020
Alternate Names:

CHEMBL1289601 ChEMBL Drug ID

Drug Info:

Publications:
TALC: LENVATINIB
- Version: 12-May-2016
Alternate Names:

LENVATINIB Primary Drug Name

LENVATINIB Drug Generic Name

E7081 Drug Synonym

Drug Info:

Publications:
TTD: Lenvatinib
- Version: 2020.06.01
Alternate Names:

D0R0FO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1289601
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Phase I

LENVATINIB	Primary Drug Name
LENVATINIB	Drug Generic Name
E7081	Drug Synonym

Notes
Trial Name	E7080
Novel drug target	Established target

Trial Name	E7080
Novel drug target	Established target
Notes

Trial Name	E7080
Novel drug target	Established target
Notes

Trial Name	E7080
Novel drug target	Established target

LENVATINIB Drug Record

LENVATINIB chembl:CHEMBL1289601 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 25295214 27496134 17943726

Sources: TALC JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name E7080 Novel drug target Established target

PMIDs: 17943726

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 25295214 17943726

Sources: TdgClinicalTrial JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Phase I

PMIDs: 26169970

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name E7080 Novel drug target Established target Notes

PMIDs: 17943726

Sources: TALC MyCancerGenome TdgClinicalTrial TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: 17943726

Sources: TALC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name E7080 Novel drug target Established target Notes

PMIDs: 17943726

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name E7080 Novel drug target Established target

PMIDs: 17943726

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name E7080 Novel drug target Established target

PMIDs: 17943726

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase I Response Type sensitive

PMIDs: 26169970

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name E7080 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

MyCancerGenome: LENVATINIB

Alternate Names: LENVATINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors FDA Approval Renal cell carcinoma, Thyroid cancer

Publications:

TdgClinicalTrial: LENVATINIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Lenvatinib

Alternate Names:

Drug Info:

CIViC: LENVATINIB

Alternate Names:

Drug Info:

Publications: Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.

DTC: LENVATINIB

Alternate Names: CHEMBL1289601 ChEMBL Drug ID

Drug Info:

Publications:

TALC: LENVATINIB

Alternate Names: LENVATINIB Primary Drug Name LENVATINIB Drug Generic Name E7081 Drug Synonym

Drug Info:

Publications:

TTD: Lenvatinib

Alternate Names: D0R0FO TTD Drug ID

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 27496134 17943726

Sources:
TALC JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25295214 17943726

Sources:
TdgClinicalTrial JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Phase I

PMIDs:
26169970

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

Notes

PMIDs:
17943726

Sources:
TALC MyCancerGenome TdgClinicalTrial TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
17943726

Sources:
TALC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

Notes

PMIDs:
17943726

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
17943726

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
26169970

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

LENVATINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Renal cell carcinoma, Thyroid cancer

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Huang et al., 2016, Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma., Mol. Cancer Ther.

Alternate Names:

CHEMBL1289601 ChEMBL Drug ID

Alternate Names:

LENVATINIB Primary Drug Name

LENVATINIB Drug Generic Name

E7081 Drug Synonym

Alternate Names:

D0R0FO TTD Drug ID